Hey there Kei. I'm hopeful getting a green light for P3 trial (and certain plans 'firmed') is the milestone needed to cement a commercial partnership with progressive tranches of funding through P3, to solve the cash problem. Regarding the funding of ongoing (non-P3) operations, it would seem imprudent to me if OPXA hadn't sold some shares into the strength we've seen since the FDA press release.
Market Data 
Markets 
AI
